Analysts Offer Insights on Healthcare Companies: Mateon Therapeutics Inc (NASDAQ: MATN) and Celldex (NASDAQ: CLDX)By Carrie Williams
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mateon Therapeutics Inc (NASDAQ: MATN) and Celldex (NASDAQ: CLDX) with bullish sentiments.
Mateon Therapeutics Inc (NASDAQ: MATN)
“Mateon announced positive data from the third cohort of the ongoing phase 1b/2 study of their second VDA (vascular disrupting agent) candidate, OXi4503, in patients with r/r AML (relapsed/refractory Acute Myeloid Leukemia).”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -10.5% and a 36.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Stellar Biotechnologies, and Inovio Pharmaceuticals.
Mateon Therapeutics Inc has an analyst consensus of Moderate Buy.
Celldex (NASDAQ: CLDX)
“CLDX reported 2016 financials and a pipeline update.”
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 4.7% and a 40.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.
Currently, the analyst consensus on Celldex is Strong Buy and the average price target is $6.50, representing an 88.4% upside.
In a report issued on March 14, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $9 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.